The Lyfstone diagnostic tests are ready for distribution to pilot clients, and will have a full scale, international commercial launch Q3-2018 Artificial joints are one of the most important medical successes of our time Unfortunately this success has created a new problem – these implants loosen over time and have to be revised Currently, diagnosis of loosening is unclear and the revision surgeries are both complex and costly Lyfstone gives surgeons and patients a clear and objective diagnostic tool for determining the need to proceed with a revision procedure or not

We have developed a system for calculating and supplying Solcelle, and wind power for Scandinavia. In addition to this, we have obtained a license as a power supplier, so we can offer our customers both purchases and sales of green power. Why solar cells? Sun provides energy. As an energy source, the sun is unsurpassed. Every year, the earth receives 15,000 times more energy from the sun than the earth's population uses. Even in Norway, the sun provides 1,500 times more energy than what we use. Depending on where on the globe you are, the sun provides an amount of energy from 700 to over 2,200 kWh/m2 per year.

eCommerce, B2B, and product development towards tactical, outdoor, and lifestyle products. Office and warehouse in Oslo and eCommerce presence 3 in Norway, Sweden, and Finland. 25 employees and 100MNOK revenue in 2018. We've been growing about 50% yearly over the last three years and aim to continue growing at the same speed. The young data-driven organization with ambitions to become the biggest player within our niche. Come and join us!

Forretningsidé Tenk hvor mye ubenyttet kunnskap vi har. Fromber er en digital plattform for privatundervisning som gjennom ny teknologi og forretningsmodell tilbyr billigere, lettere tilgjengelig og større effekt av det du ønsker å lære mer av. Med Fromber kan du som bruker lære mer og som talent hjelpe andre å bli bedre, med formål om å ta ett skritt frem med en som er ett skritt foran. Fromber er derfor både et marked som verdsetter din kunnskap og et sentrum for læring. Mål: Bli sentrum for all privatundervisning i Norge, for så å ekspandere til Norden. Deretter Europa og tilslutt å innta en identisk posisjon som Uber har for taxi, gjennom privatundervisning, tilgjengelig for mennesker i alle deler av verden. Visjon: Fromber har en visjon om å gjøre privatundervisning tilgjengelig for alle.

Kikora is one of Norway's leading digital edtech companies. We provide an e-learning platform for mathematics. Our unique maths engine and technology platform contributes to better learning among several hundred thousand Norwegian students. We consider ourselves one of the best places in edtech to work. Over half of Norway's students use Kikora, and we are growing.

The Founder Institute is the world’s premier startup launch program for talented entrepreneurs. If you are up to the challenge, our comprehensive step-by-step program will give you the structure, mentor support, and network of entrepreneurs you need to start an enduring company. Based in Silicon Valley and with chapters across 60 countries, the Founder Institute's mission is to "Globalize Silicon Valley" and build sustainable startup ecosystems worldwide.

Emberly is a Stavanger-based startup founded in 2020. The company was born out of a desire to help people learn better and to help them manage information overload. Our product is a knowledge library, but in contrast to other solutions, we help you organize your knowledge into what we call "knowledge maps". Traditional solutions based on tags and search are not adequate due to the simple fact that it requires using the language center of the brain, this requires you to break your chain of thought before you can even start looking for your resources. Emberly in contrast, lets you use spatial navigation to find what you are looking for. Which is far more efficient.Not to mention the fact that by creating and using this breakdown of topics, you automatically gain a far better understanding of the concepts you are working on. We have been working tightly knit with our community for two years to help us make Emberly the best experience it can be, and we officially released the system in 2022.

Handlekraftig AS is an attempt at doing slightly more for the environment than just sorting trash and buying as little plastic as possible. For now, this is a single organic shop where most products are sold in bulk/lose weight. We encourage our customers to bring in their own containers to shop, to minimize the need for new packaging. We try to keep at least 95% of the consumables organic. This is better for our customers and better for the earth. In addition to organic foodstuff, we also offer a wide selection of zero-waste products, such as beeswax wraps, wooden kitchen utensils, and non-plastic containers.

Oncoinvent AS is a privately held Norwegian company established in 2010. The company is committed to developing new innovative products to provide better treatment options to cancer patients. The innovations being developed by Oncoinvent AS are a result of the extensive experience with the development of radionuclide-based cancer treatments of two of the founders, Dr. Roy H. Larsen and Professor of clinical oncology Øyvind S. Bruland. Larsen and Bruland are the inventors of the first FDA and EMA-approved alpha-emitting pharmaceutical product Xofigo® (Bayer AG), as well as of the beta-emitting radio-immunotherapeutic product candidate Betalutin® (Nordic Nanovector ASA). Oncoinvent's lead product candidate, Radspherin®, is a novel alpha-emitting radioactive microsphere designed for the treatment of metastatic cancers in body cavities. Radspherin® has been shown to cause a significant reduction in tumor cell growth. It is anticipated that the product can potentially treat several forms of metastatic cancer. The first clinical indication for Radspherin® will be the treatment of peritoneal carcinomatosis. Clinical development will be conducted in collaboration with European and American clinical research centers.

Biozep is discovering and developing first-in-class drug products for the treatment of severe eye diseases which can lead to vision loss and where it is a high unmet medical need. Biozep has discovered novel drug substances based on bioactive lipids which modulate central pathways involved in the pathogenesis of eye diseases. Targets and biomarkers are identified based on a system biology approach combined with in-depth knowledge about bioactive lipids, their endogenous synthesis and mechanisms of action. Biozep has made a prototype drug product based on our lead compound for topical administration and the product will be tested in animal models in 2018. Our goal is to start clinical studies in 2020. Biozep is a company depending on both internal and external resources. Biozep has established its own laboratory in Oslo in order to do synthesis, purification, quality control and chemical development in-house. The biological testing of the drug substances is performed in collaboration with carefully selected contract research organizations both in Europe and the USA. In order to reach the market as fast as possible and to reduce risk, Biozep will seek strategic partnerships early in the drug development phase. Biozep seeks partners with complementary competence and with resources to conduct clinical trials and with market access. We are already in dialogue with potential partners and hope to sign an agreement in 2018-19.

OncoImmunity is a bioinformatics company providing unique machine-learning software to identify tumor-specific mutations that can be targeted by a patient’s own immune system (known as neoantigens). The OncoImmunity solution is important because recent breakthroughs in the field of Immuno-Oncology (I-O) such as the development of checkpoint inhibitors and personalized cancer vaccines, clearly demonstrate that a patient’s immune system can be harnessed to successfully treat cancer. The cost of identifying tumor-specific mutations in a patient’s cancer using next-generation sequencing (NGS) is now trivial and this technology will be key to enabling truly personalized immunotherapies to be developed in a technically and economically feasible manner. However, the remaining challenge that currently limits the field, and which is addressed by the OncoImmunity solution, is predicting which tumor-specific mutations can stimulate a patient’s immune system i.e. are immunogenic. Using NGS data as input, the OncoImmunity software enables accurate patient selection for cancer immunotherapy and can identify optimal targets for personalized cancer vaccines & cell therapies in a clinically actionable time frame. Beginning from this first product offering, OncoImmunity has the vision to become the world’s leading provider of software to guide cancer immunotherapy to improve survival rates for cancer patients. To achieve this OncoImmunity has assembled a growing team of world-class bioinformaticians, data scientists, and software engineers; developing its cutting-edge machine-learning technology that will help fulfill the promise of immunotherapy in the fight against cancer. OncoImmunity’s technology will disrupt the I-O field by offering regulatory-compliant prediction software on a software-as-a-service basis (SaaS). This will allow big pharma, biotechnology, and immunotherapy companies of any size to access OncoImmunity’s cutting-edge prediction software. The company is headquartered in an ideal scientific and entrepreneurial ecosystem to develop its technology at the Oslo Cancer Cluster Incubator; adjacent to the Institute for Cancer Research and the Norwegian Radium Hospital. OncoImmunity is a privately held company, founded in 2014 by experienced bioinformatics scientists (Dr. Trevor Clancy and Professor Eivind Hovig), and an experienced immunologist with a business development background (Dr. Richard Stratford). The company is backed by private financing from the Norwegian Radium Hospital Research Foundation, the Norwegian Cancer Society, STARTUPLAB, and Grotmol Solutions, in addition to a number of private software investors. The company is also supported by grants awarded from the Norwegian Research Council, Innovation Norway, and the EU. The company has already established both national and international collaborations and pilot projects to develop further proof-of-concept data and validate its software.

LifeTools AS develops digital tools for people with complex needs within the fields of communication, cognition, and challenged behavior. We put the user first and develop dynamic systems with high flexibility based on the unique user's needs. The network around the user will have digital tools to observe, build and publish expressions, routines, and activities into our systems, and use this information back into the interaction with the user. This gives a better foundation in communication and helps increase the quality of life for the user. Our philosophy is to use "everyday technology" such as tablets/phones and cloud-based solutions and develop highly intuitive and dynamic tools for the network. Users (people with special and complex needs) therefore do not need to acquire skills or knowledge in order to use our systems. This makes it easier for those who have great cognitive challenges to make use of our technological solutions.

We provide the banking network, messaging, settlement, and cash management solutions to meet any bank’s requirements. We are based in Fredrikstad, Norway, where UNITE evolved as a correspondent hub for banks, but our origin is global, developed over years in international banking centers. We have studied other initiatives over the years and learned that the third-party philosophy of trying to bolt-on smart software to multiple bank accounts is less than ideal. A holistic revolution was required to deliver a cross-border payments solution fit for banks in the 21st century.

An employee management system that´s designed to be easy to use. By thinking differently and smarter than our competitors we are making an employee management system that is easy to use, especially for elderly users. And the system is not complicated. We are focusing on that our typical customer is both 20 and 60 years old. Therefore is it important for us to listen to them, so we can make a system that is understandable for them. By getting satisfied customers, we will be the preferred system for small and medium-sized businesses. We are providing a web-based system that is available on all devices. In our system, you find timesheets, deviation, weekly plans/schedules, resource-planner, groups, CRM, newsfeeds, to-do-list, use on projects, travel logs, and many more tools for communication and registration. We want to make a smart and effective day for small and medium businesses. KPI - Key Performance Indicator:- MVP - Minimum Viable Product- 20 costumers- Founding from Innovation Norway (marked clarification)- 2016 revenue: 318.000NOK

Hei, mitt navn er Erik Johannesen og er gründer i det norske selskapet ID TAG TECHNOLOGY GROUP AS. Selskapet ID TAG TECHNOLOGY har en idé og teknologi som vi anser som støttende til innsamling av BIG DATA, og et utall andre muligheter innenfor dette konseptet. Vår ambisjon er at ID TAG TECHNOLOGY skal kan skape et nytt verdensomspennende markedsføringskonsept. ID TAG TECHNOLOGY sin patenterte teknologi/konsept har til hensikt å være en «plattform» for mange industrielle behov. Vi anser at vi kan lisensiere ut vår teknologi til logistikk, broadcast, marine, olje og gass mm. Utallige muligheter. Tenk deg at du tar et bilde med mobilkamera og kan se hvem som er på bildet med informasjon om vedkommende, samt at du kan se hvilken merkevare-/produsent som har produktene på bildet, i sanntid. Deretter trykker du på produktet på bildet som inneholder en url, og du blir sendt videre til produktets nettsted. Dette er ikke gjenkjennelses teknologi eller maskin learning, men rett informasjon som er skapt av de som ønsker å informere kundene i den store verden. ID TAG TECHNOLOGY ble etablert 2011, har en positiv PCT-rapport, og innleverte patentsøknader februar 2015 på en teknologi/konsept for å plassere/identifisere elektroniske tags/sensorer innenfor en billedramme i sanntid, både stillbilder og video/film i en rekke land. Både ideen og teknologien har oppfinnerhøyde. Teknologien som er beskrevet i patentsøknadene er utviklet/forsket på i samarbeid med SINTEF, og har pågått siden begynnelsen av 2011. Vi har nå utviklet en lab modell for å bevise at dette lar seg gjennomføre – dette kan du få se. ID TAG TECHNOLOGY GROUP har blitt innvilget patent i Norge, USA og Kina (2017). Det er for øvrig søkt patent i EPO, Russland, Hong Kong, Japan og Sør Korea. Søknadsprosessen går over all forventning. Teknologien kan benyttes både i profesjonelt utstyr og i personlige enheter som smarttelefoner og nettbrett/PC og egenutviklede hardwareprodukter for industrielle behov. Bruksområdene er mange, og vi har spesielt sett på kringkasting/film (produktplassering), markedsføring/varehandel, transport/distribusjon og sosiale medier. Vi ser store muligheter innenfor markedsføring og salg hvor interessenten har mer kontroll enn det som dagens trender tilsier.   Se gjerne våre illustrerende konsept filmer på vår hjemmeside: http://www.idtagtech.com  Med vennlig hilsen  Erik Johannesen Mob: +47 918 71 610 E-mail: erik.johannesen@bbnett.no Hjemmeside: http://www.idtagtech.com